Filing summary
Issuer and period: The supplied filing is Edge Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 2, 2017. This does not match the request metadata identifying PDS Biotechnology Corp.; verify the issuer before relying on this summary.
Business context and reporting period
Edge was a clinical-stage biotechnology company with no approved products or product sales. Its lead candidate, EG-1962, is a sustained-release formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH). In July 2016, the company began the pivotal Phase 3 NEWTON 2 study. EG-1964, for preventing recurrent bleeding in chronic subdural hematoma, remained preclinical. The company reported under U.S. GAAP.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $24.8 million | $17.8 million |
| General and administrative expense | $14.7 million | $8.7 million |
| Total operating expenses | $39.5 million | $26.5 million |
| Net loss | $38.8 million | $28.1 million |
| Basic and diluted loss per share | $1.34 | $4.01 |
| Cash and cash equivalents at year-end | $106.4 million | $130.2 million |
| Net cash used in operating activities | $32.2 million | $21.8 million |
| Debt carrying value at year-end | $15.0 million, long-term | $5.3 million, current and long-term |
FY 2016 operating expenses rose 49% and net loss rose 38%, primarily reflecting expanded EG-1962 development and higher personnel, stock compensation, facilities, insurance and professional costs. Cash declined by $23.8 million during the year; financing cash flow included net debt proceeds. The company reported no operating margins because it had no revenue. It stated that available cash was expected to fund operations through the anticipated late-2018 NEWTON 2 readout, but noted this estimate depended on uncertain assumptions.
For Q4 2016, operating expenses were $10.9 million and net loss was $9.5 million, compared with $8.9 million and $8.0 million, respectively, in Q4 2015.
Material changes and development update
- NEWTON 2 was initiated in 2016, comparing a single 600 mg EG-1962 dose plus placebo with standard oral nimodipine. The primary endpoint is favorable GOSE outcome at day 90; interim analysis was expected in early 2018, with full results anticipated in late 2018 if the trial continued.
- In the earlier, small Phase 1/2 NEWTON study, 60% of EG-1962-treated patients (27/45) had favorable outcomes versus 28% (5/18) of oral-nimodipine controls. These exploratory results are not definitive evidence of Phase 3 success.
- R&D spending on EG-1962 increased by about $5.0 million year over year; the company attributed the overall R&D increase principally to that program and additional internal personnel.
- The company amended its Hercules loan in August 2016, borrowing $15 million and retaining an option to draw an additional $5 million by June 15, 2017. The loan bears 9.15% interest at year-end, is interest-only through March 2018, and is scheduled to mature in February 2020.
Outlook, risks and unusual items
- Management expected R&D and G&A spending to increase and anticipated continued losses; product revenue depended on successful development, regulatory approval and commercialization.
- Key risks include Phase 3 failure or delay, the need for additional trials, manufacturing scale-up and reliance on single-source suppliers, and dependence on external clinical and manufacturing providers.
- U.S. approval timing for EG-1962 could be affected by Nymalize’s orphan-drug exclusivity through May 2020. The company said it would need to establish clinical superiority or otherwise resolve the exclusivity issue to seek earlier approval.
- The Hercules debt is secured by substantially all assets other than intellectual property, which is subject to a negative pledge; it includes restrictive covenants, fees, and prepayment charges. The company warned that additional financing could be needed and could dilute shareholders.
- FY 2016 included $1.85 million of income-tax benefit from selling New Jersey tax attributes, $0.16 million of other expense related to relocation asset disposal and debt issuance costs, and increased interest expense. The company reported no material legal proceedings and no off-balance-sheet arrangements.
- The audited financial statements received an unqualified opinion from KPMG. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation under the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Confirm that Edge Therapeutics—not PDS Biotechnology—is the intended issuer and that the relevant reporting period is FY 2016.
- Check current NEWTON 2 status, endpoints, enrollment, interim-analysis outcomes and any subsequent regulatory communications; the timelines here are management’s 2017 expectations.
- Review cash burn against the stated late-2018 runway assumption, including any additional clinical-trial requirements or financing.
- Verify outstanding Hercules principal, any additional tranche draws, repayment terms, covenants and fees.
- Assess the clinical-superiority and exclusivity pathway relative to Nymalize, as well as the company’s supply-chain and manufacturing readiness.